Formycon AG (LTS:0W4N) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Formycon AG 5-Year EBITDA Growth Rate?

Formycon AG's EBITDA per Share for the six months ended in Dec. 2024 was €0.12.

During the past 12 months, Formycon AG's average EBITDA Per Share Growth Rate was -104.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 40.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Formycon AG was 71.50% per year. The lowest was -120.40% per year. And the median was 28.20% per year.

Competitive Comparison of Formycon AG's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Formycon AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Formycon AG's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Formycon AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Formycon AG (LTS:0W4N) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Formycon AG 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Formycon AG's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

FYB:Germany

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Formycon AG Headlines

No Headlines